Analysis

3 Trial Losses Won't Doom Xarelto Patients

Law360, New York (August 23, 2017, 12:47 PM EDT) -- After a hat trick of defense wins for Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. in bellwether trials over blood thinner Xarelto, consumers face an uphill — but not impossible — task of turning the tide in their favor.

So far, consumers in three bellwether trials have been unable to persuade jurors that Bayer and Janssen didn’t adequately instruct their treating physicians about the risks of dangerous internal bleeding associated with the blood thinner. Attorneys noted that a string of victories is unusual in bellwether trials in pharmaceutical litigation, as usually verdicts are more mixed, but...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS